← Back to Search

Diagnostic Test

Treatment for Bladder Cancer

N/A
Recruiting
Led By Hideki Furuya
Research Sponsored by Cedars-Sinai Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 5 years
Awards & highlights

Summary

To improve upon the non-invasive detection of bladder cancer by further validating a multiplex ELISA assay directed at a bladder cancer-associated diagnostic signature in voided urine samples of patients with a high risk of developing bladder cancer.

Eligible Conditions
  • Bladder Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 5 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
1. To assess the ability to recruit and retain an appropriate high-risk group of subjects into a 4-year longitudinal study monitoring them for the development of bladder cancer.
2. To report the sensitivity and specificity of the multiplex immunoassay ability to detect bladder cancer in patients with high risk of developing bladder cancer: >50 years and >40 pack year history of tobacco exposure.
3. To develop a prediction risk calculator from this cohort using cutting edge machine learning techniques (e.g., random forest) incorporating biomarker data and clinical data.

Find a Location

Who is running the clinical trial?

VA Long Beach Healthcare SystemFED
15 Previous Clinical Trials
4,295 Total Patients Enrolled
Cedars-Sinai Medical CenterLead Sponsor
509 Previous Clinical Trials
165,713 Total Patients Enrolled
Nonagen Bioscience CorporationIndustry Sponsor
4 Previous Clinical Trials
2,050 Total Patients Enrolled
~78 spots leftby Mar 2026